BioMarin shares rise as new VOXZOGO and PALYNZIQ data reinforce market potential
Discover how BioMarin’s latest clinical data on VOXZOGO and PALYNZIQ at ACMG 2025 offers promising insights into rare disease treatments and what it means for ... Read More
FDA expands VOXZOGO approval for all ages with open growth plates
BioMarin Pharmaceutical Inc., a leading global biotechnology entity, unveiled that its drug, VOXZOGO (vosoritide), has received the green light from the U.S. Food and Drug ... Read More